Health2 years ago
Neoadjuvant nivolumab offers sustained efficacy in resected NSCLC
Treatment with neoadjuvant nivolumab (Opdivo) improves 5-year recurrence-free survival (RFS) and overall survival compared with historical outcomes in patients with surgically resected non-small cell lung cancer...
Recent Comments